First Tricuspid Valve Repair Performed Using Edwards Lifesciences' PASCAL Precision System
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the U.S. using the PASCAL Precision system following FDA approval.
Stocks · News reference
Edwards Lifesciences Partners with egnite and Pathway Labs for Structural Heart Disease Identification
Edwards Lifesciences is funding a pilot program with egnite and Pathway Labs to improve the early identification of patients with structural heart disease.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NCH Rooney Heart Institute Performs Nation’s First Tricuspid Valve Repair with PASCAL Precision System Following FDA Approval
Naples Comprehensive Health (NCH) has performed the nation's first tricuspid valve repair using Edwards Lifesciences' PASCAL Precision system following FDA approval. The procedure expands minimally invasive treatment options for patients with severe tricuspid regurgitation, building on NCH's role as the highest-enrolling clinical trial site for the therapy.
Edwards Lifesciences Receives FDA Approval for Tricuspid Valve Repair System
Edwards Lifesciences has secured US FDA approval for its tricuspid valve repair system, marking a significant milestone for its structural heart disease portfolio.